Pharma BD Deal Intelligence
Total loss: stannsoporfin was rejected by FDA and fully written off within two years of closing, with zero product revenue ever generated
Full analysis, sources & comparables →Mallinckrodt agreed to acquire InfaCare and stannsoporfin to expand its hospital and specialty franchise; the heavily milestone-weighted $425M structure…
FDA issued a Complete Response Letter for stannsoporfin following a 21-3 advisory committee vote against approval, citing insufficient evidence of…
Stannsoporfin's FDA rejection following the unfavorable AdComm vote effectively closed the path to a near-term first-in-class neonatal jaundice drug, leaving…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
Mallinckrodt agreed to acquire InfaCare Pharmaceutical, gaining stannsoporfin, a Phase 3 heme oxygenase inhibitor in development for severe neonatal hyperbilirubinemia. Deal structure: $80M upfront plus up to $345M in development, regulatory and sales-based milestones (~$425M aggregate). The deal expanded Mallinckrodt's hospital/specialty franchise. Stannsoporfin later faced an FDA refuse-to-file letter.
Total loss: stannsoporfin was rejected by FDA and fully written off within two years of closing, with zero product revenue ever generated
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Mallinckrodt plc / InfaCare Pharmaceutical Corporation (this deal) | 2017 | $425M | 12 |
| Mallinckrodt plc / Cadence Pharmaceuticals, Inc. | 2014 | $1.4B | 50 |
| Mallinckrodt plc / Therakos, Inc. | 2015 | $1.3B | 48 |
| Mallinckrodt plc / Ikaria, Inc. | 2015 | $2.3B | 37 |
| Mallinckrodt plc / Sucampo Pharmaceuticals, Inc. | 2017 | $1.2B | 19 |
| Mallinckrodt plc / Questcor Pharmaceuticals, Inc. | 2014 | $5.6B | 18 |
| Watson Pharmaceuticals (Actavis Inc.) / Actavis plc | 2012 | $5.9B | 97 |
← Browse all deals · How we score deals
More: 2017 deals · Mallinckrodt plc deals · Other deals